Citations

Clear

3042 citation(s) found for "Kumar, S".

Hormonal influences on asthma phenotypes and endotypes during the menopausal transition
Kumar, Ashish , Zein, J G, Silveyra, Patricia , Zein, Joe G, Zein, Joe

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | June 9, 2026 | Volume: 331 | Issue: 1 | Pages: L79-L88

10.1152/ajplung.00170.2026 | PMID 42262513 Get It

This review identifies the menopausal transition as a critical yet underrecognized determinant of asthma heterogeneity in midlife women. It synthesizes evidence that fluctuating sex hormones may shape distinct asthma phenotypes and endotypes, influencing clinical manifestations, disease modifiers, and therapeutic responses. By framing menopause-associated asthma as a biologically distinct, hormone-driven condition, the article highlights key research priorities for precision medicine approaches tailored to women’s respiratory health.
Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis
Steinhardt, Maximilian J., Hegenbart, Ute , Hellou, Tamer , Oubari, Sara, Roussel, Murielle , Schwotzer, Rahel , Buadi, Francis, Dingli, David, Kourelis, Taxiarchis, Zanwar, Saurabh , Rieger, Max J., Morbach, Caroline, Cejka, Vladimir , Störk, Stefan, Einsele, Hermann, Kumar, Shaji, Gertz, MA, Carpinteiro, Alexander , Kortum, K. Martin, Dispenzieri, Angela, Steinhardt, Maximilian , Steinhardt, Maximilian , Zanwar, Saurabh S , Rieger, Max J , Cejka, Vladimir , Gertz, Morie A , Muchtar, E , Hegenbart, Ute , Roussel, Murielle , Buadi, Francis K. , Dingli, David , Binder, Moritz , Kourelis, Taxiarchis , Morbach, Caroline , Gerber, B. , Störk, Stefan , Kumar, Shaji, Gertz, Morie A. , Kortüm, Martin , Muchtar, Eli , Dispenzieri, Angela , Schönland, Stefan

Mayo Clinic

American Journal of Hematology | June 8, 2026 | Volume: 101 | Issue: 8 | Pages: 1903-1914

10.1002/ajh.70371 | PMID 42252535 Get It

ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM within 12 months at six centers in Europe and the United States between 2010 and 2024 to evaluate outcomes by baseline risk factors, hematologic response, and receipt of HDM. Death was an equally competing risk after the 12‐month landmark chosen to address early non‐proportional hazards and to ensure completion of first‐line therapy. BMPC > 20% was associated with inferior outcomes (HR 1.7), and gain/amp 1q with shorter TTP (HR 2.15), whereas other high‐risk FISH abnormalities were not. In multivariable models, VGPR/CR after standard intensity therapy was associated with longer TTP (HR 0.49/0.29), while gain/amp 1q remained independently associated with shorter TTP (HR 2.18). Receipt of daratumumab and HDM were associated with longer TTP (HR 0.44/0.61). HDM benefited patients who had not achieved CR after standard intensity therapy (mTTP 21.0 vs. 5.7 months without HDM), whereas patients already in CR did not benefit. Higher BMPC at diagnosis was associated with earlier progression in patients not receiving HDM (HR 1.9 for 5%–20% and 4.09 for > 20%), a risk attenuated in the HDM cohort. Gain/amp 1q remained associated with shorter TTP regardless of HDM exposure. These findings support a selective role for HDM, primarily benefiting patients with residual disease after standard intensity therapy or higher BMPC burden at diagnosis.
A Multiregional Decentralized Clinical Trial Program to Improve Access
Haddad, Tufia C. , Mercado, Lydia A., Enarson, David A., Sener, Ugur, Price, Katharine A., Juhn, Young J., Cartin‐Ceba, Rodrigo , Colón‐Otero, Gerardo , Kottschade, Rebecca S., Le‐Rademacher, Jennifer , Sener, Uğur , Kumar, Amanika , Juhn, Young J. , Willman, Cheryl L. , Garovic, Vesna D.

Mayo Clinic

JAMA Network Open | June 5, 2026 | Volume: 9 | Issue: 6 | Pages: e2617204

10.1001/jamanetworkopen.2026.17204 | PMID 42247228 Get It

Importance Decentralized clinical trials (DCTs) aim to increase trial access for underrepresented populations (URP) and ensure study outcomes, conclusions, and policy-related decisions are applicable to diverse populations. Objective To assess trends in the percentage of accrued participants from more than 120 miles from the research site upon DCT program implementation. Design, Setting, and Participants This descriptive quality improvement study was conducted from January 2024 to March 2025 at Mayo Clinic, a US multiregional, academic medical center (AMC) comprising 3 sites and an affiliated, community-based health care system. All individuals who consented and/or accrued to an institutional review board–approved clinical trial were included. Exposure DCTs are defined as trials with at least 1 decentralized capability beyond remote consent. DCT program development began July 2022. By January 2024, remote consent, video telehealth visits, remote phlebotomy, and device services were implemented across all sites and departments. Remote monitoring and oral medication delivery were available on a limited basis. Prospective automated program and DCT participant data collection and quarterly reporting began in January 2024. Main Outcomes and Measures Percentage of all DCT accrued participants with a residential zip code more than 120 miles from 1 of 3 AMC sites. Results There were 7469 participants (median [IQR] age, 62 [51-70] years; 3594 [48.1%] female; 241 [3.2%] Asian, 391 [5.2%] Black or African American, and 6347 [85.0%] White individuals) accrued to 765 DCTs. During the study period, the percentage of DCT participants residing more than 120 miles from an AMC site ranged from 18.9% in the first quarter (Q1) of 2024 (383 of 2032 participants) to 29.6% in Q1 of 2025 (346 of 1170 participants). Of those accrued, 1147 (15.4%) were of a racial or ethnic URP, ranging from 12.5% in Q1 of 2024 (253 participants) to 17.4% in Q1 of 2025 (204 participants). There were 1554 (20.8%) participants from a rural location, ranging from 16.6% in Q1 of 2024 (338 participants) to 24.9% in Q1 of 2025 (291 participants). Additionally, by geospatial distance from an AMC site, the male-to-female ratio was nearly 50:50, and the age distribution appeared similar. Conclusions and Relevance In this quality improvement study of a DCT program implementation, DCT accruals trended favorably among those residing more than 120 miles from an AMC site and those of rural or URP populations. While these findings cannot be directly attributed to program implementation, they are reassuring that this strategy may address some barriers to clinical trial access. Future studies should assess the sustained effectiveness and scalability of DCT models in improving equitable trial access.
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia
Packard, D, Kumar, Shaji K., Dispenzieri, Angela, Kapoor, Prashant , Janda, Guneet , Hellou, Tamer , Dingli, David, Zanwar, Saurabh , Jevremovic, Dragan, Hayman, Suzanne R. , Abdallah, Nadine, Warsame, Rahma, Kourelis, Taxiarchis , Christenson, Lisa, Hobbs, Miriam, Fonder, A., Pak, Karen, Lee, Lee H. , Lin, Yi, Gertz, MA, Gonsalves, Wilson I., Packard, Daniel George , Packard, Daniel G , Leung, Nelson , Cook, Joselle M , Abdallah, Nadine H , Muchtar, E , Kourelis, Taxiarchis V, Go, Ronald S , Siddiqui, Mustaqeem A , Gertz, Morie A , Rajkumar, S Vincent , Kumar, Shaji , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Jevremović, Dragan , Leung, Nelson , Cook, Joselle , Abdallah, Nadine , Binder, Moritz , Muchtar, Eli , Warsame, Rahma , Go, Ronald S. , Siddiqui, Mustaqeem , Christenson, Lisa, Hobbs, Miriam, Fonder, Amie , Lee, Lee H., Lin, Yi, Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson I.

Mayo Clinic

American Journal of Hematology | June 4, 2026 | Volume: 101 | Issue: 9 | Pages: 2157-2165

10.1002/ajh.70400 | PMID 42237452 Get It

ABSTRACT Primary plasma cell leukemia (pPCL) is a rare and aggressive plasma cell disorder with inferior outcomes compared with multiple myeloma (MM). However, studies describing outcomes after first progression and subsequent lines of therapy remain limited. We retrospectively analyzed 104 patients with pPCL who progressed after first‐line therapy treated at one comprehensive cancer center between 2006 and 2024. Clinical characteristics, treatments, time to next treatment (TTNT), and overall survival (OS) were assessed using Kaplan–Meier methods. All pPCL patients received novel agent–based induction. At the time of analysis, 63% had died; median OS was 39 months. High‐risk cytogenetics were present in 71%. The median TTNT after first‐line therapy was 10 months. Symptomatic progression occurred in 29% of patients and was associated with significantly inferior subsequent OS (13 vs. 34 months) compared with those experiencing asymptomatic biochemical progression. The TTNT progressively shortened with subsequent lines of therapy (3rd line: 6 months; 4th line: 4 months; 5th line: 3 months). Notable exceptions included pPCL patients with t (11;14) treated with anti‐BCL‐2‐based regimens, who achieved a median TTNT of 13 months. Additionally, 24 patients received anti‐BCMA CAR T‐cell therapy. With a median follow‐up of 21 months, their median TTNT was 32 months. pPCL is characterized by frequent disease progression and diminishing response duration with successive therapeutic lines. Symptomatic progression portends particularly poor outcomes. Anti‐BCL‐2‐based therapy in t (11;14) disease and anti‐BCMA CAR T‐cell therapy appear to provide more durable disease control and represent important advances for the management of progressed pPCL.
Potential Clinical Impact of Sinonasal Biofilms in CRS: A Structured Evidence Synthesis
Holley, Hunter A. , Kumar, Nitish , Segovia, Diana , Lal, Devyani , Miglani, Amar , Marino, Michael J. , Almader‐Douglas, Diana , Kumar, Nitish , Lal, Devyani , Holley, Hunter

Mayo Clinic

International Forum of Allergy & Rhinology | June 3, 2026 | Volume: 16 | Issue: 8 | Pages: 880-885

10.1002/alr.70197 | PMID 42233275 Get It

High Versus Low Radiographic Burden Odontogenic Sinusitis: Culture, Histopathology, and Patient‐Reported Outcomes
Ebbert, Landon E. , Kumar, Nitish , Lal, Devyani , Miglani, Amar , Marino, Michael J. , Kumar, Nitish , Lal, Devyani

Mayo Clinic

Laryngoscope Investigative Otolaryngology | June 2, 2026 | Volume: 11 | Issue: 3 | Pages: No page available

10.1002/lio2.70456 | PMID 42257217 Get It

ABSTRACT Objective Odontogenic sinusitis (ODS) ranges from isolated maxillary disease to pansinusitis. We compared patient characteristics, microbial and histopathological features, and symptom outcomes following endoscopic sinus surgery (ESS) between low and high radiographic burden ODS patients. Methods ODS patients undergoing ESS between 01/2013 and 08/2024 were reviewed. Preoperative CT scans were used to classify patients into high radiographic burden [with ostiomeatal complex (OMC) opacification] and low radiographic burden ODS [clear OMC]. Demographic, microbiological, and histopathological data were analyzed. Symptom improvement was assessed using pre‐ and post‐operative SNOT‐22 scores. Results Eighty‐seven patients were identified (high CT burden: 70; low CT burden: 17). High CT burden ODS was associated with older age ( p = 0.014), higher overall degree of inflammation ( p = 0.002), hyperplastic/papillary epithelial changes ( p = 0.034), and neutrophil infiltration ( p = 0.003). Culture of classic ODS bacteria ( Fusobacterium spp., Prevotella spp., mixed anaerobes, Streptococcus anginosus group) did not correlate with CT disease burden ( p = 0.110). No independent predictors of radiographic high‐burden disease were identified. Post‐ESS, significant reduction in total and rhinologic SNOT‐22 scores was only observed in the radiographic high‐burden ODS group ( n = 39; median reductions: 23 and 12 respectively; p < 0.001). Conclusion High radiographic burden was associated with older patients and with tissue inflammation level. Classic ODS bacterial profile did not associate with increased CT burden. While these findings remain exploratory, the observed differences in inflammatory and symptomatic profiles between groups suggest that radiographic burden warrants further study as a potential factor in ODS clinical decision‐making. Level of Evidence 3.
Real-world impact of a sepsis early detection model integrated into clinical workflow: a quasi-experimental study
Zhang, Yifan , Trinh, Sarolta H., Phelan, Tom, Byrd, Thomas F., Tourani, Roshan , Kumar, Vipin , Melton, Genevieve B., Simon, György , Trinh, Sarolta Haiyen , Phelan, Tom, Byrd, Thomas F. , Caraballo, Pedro J. , Melton, Genevieve B.

Mayo Clinic

No container title available | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.22.26353890 Get It

Abstract Background Sepsis is a life-threatening condition in which delayed recognition and treatment are associated with increased mortality. While predictive models such as Epic’s Early Detection of Sepsis Model (ESM) were developed to support early intervention, their real-world impact after integration into clinical workflows remains difficult to evaluate. Objectives To evaluate the real-world impact of ESM integrated into clinical workflow on clinical outcomes, antibiotic use, and harm-benefit tradeoffs. Methods We conducted a quasi-experimental study in a single healthcare system using encounter-level data from inpatient settings. Inpatient mortality, prolonged hospitalization, antibiotic use, and sepsis prevalence were compared between the pre-implementation period (3 June 2023 to 20 August 2024) and the online period (21 August 2024 to 26 December 2024) when the model became visible to clinicians. We also applied a counterfactual framework using models trained on pre-implementation data to estimate expected outcomes without ESM and to quantify harms related to overtreatment and delayed treatment. Results Among 101,138 encounters, 86,884 occurred during the pre-implementation period and 14,254 during the online period. In unadjusted analyses, the online period had lower inpatient mortality, prolonged hospitalization, antibiotic use, and sepsis prevalence (all p≤0.002). In the counterfactual analyses, observed outcomes were lower than expected without ESM for mortality (1.21% vs 1.82%; p<0.001), prolonged hospitalization (5.56% vs 7.95%; p<0.001), and antibiotic use (43.52% vs 47.04%; p<0.001). False positive harm (37.72% vs 41.68%; p<0.001) was also lower than expected. Conclusions Integration of ESM into clinical workflow was associated with improved patient outcomes, reduced antibiotic use, and decreased harm from overtreatment, without evidence of increased harm from delayed treatment, supporting a positive net clinical benefit and the safety and effectiveness of ESM under Software as a Medical Device principles.
Darier disease—A review highlighting new insights from the Darier Disease International Task Force
Labbouz, Sofia , Xiong, Grace , Murrell, Dedee Frances, Mueller, Simon M. , Mohandesi, Nessa Aghazadeh, Aldhaheri, Ahmed Salem, Asayag, Nissim, Baselga, Eulalia, Nadler, Chen , Chu, Chia‐Yu , Edminister, John R. , Guenova, Emmanuella, Gönülal, Melis , Gostynski, Antoni, Gupta, Lalit Kumar, Mazereeuw‐Hautier, Juliette, Hoetzenecker, Wolfram , Itin, Peter, Jankowski, Marek , Medvecz, Márta, Moosbrugger‐Martinz, Verena , Paller, Amy S., Plázár, Dóra , Queiróz, Amadeu José Rodrigues , Riera‐Monroig, Josep , Rosa, Ralph, Schmuth, Matthias, Freire, Maella Severino , Shabat, Itzhak, Shapiro, Jonathan , Soto‐García, Diego , Stratigos, Alexander J., Tadini, Gianluca Abel, Takeichi, Takuya , Verma, Kaushal K. , Wikström, Jakob D. , Ziv, Michael , Dodiuk‐Gad, Roni Pircha, Xiong, Grace , Mueller, Simon M , Ezzedine, Khaled , Choate, Keith , Gostynski, Antoni , Gupta, Ankan , Hoetzenecker, Wolfram , Jankowski, Marek , Kubo, Akiharu , Lee, Haur Yueh , Lehman, Julia Scott, Mellerio, Jemima E , Queiróz, Amadeu José Rodrigues , Freire, Maella Severino , Shapiro, Jonathan , Soto-García, Diego , Takeichi, Takuya , Wikström, Jakob D , Zink, Alexander , Navarini, Alexander , Hovnanian, Alain , Murrell, D F , Aghazadeh, Nessa , Aldhaheri, Ahmed S., Guenova, Emmanuella , Gönülal, Melis , Mazereeuw‐Hautier, J. , Lehman, Julia S. , Lepekhova, Anfisa A. , Medvecz, Márta, Paller, Amy S. , Schmuth, Matthias , Simpson, Cory L. , Tadini, Gianluca , Wikström, Jakob D. , Dodiuk‐Gad, Roni P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70483 | PMID 42223188 Get It

Abstract Darier disease (DD) is a rare autosomal dominant genodermatosis. This comprehensive review, developed by the Darier Disease International Task Force (DDITF), consolidates current knowledge on the genetic basis, molecular pathophysiology, clinical presentation, diagnosis and management of DD, offering a global perspective that unites shared expertise. The disease arises from pathogenic variants in the ATP2A2 gene, which encodes sarco/endoplasmic reticulum Ca 2+ ‐ATPase isoform 2 (SERCA2), leading to disrupted calcium homeostasis and impaired desmosomal integrity. Clinically, DD is classified based on lesion type (classic vs. non‐classic) and is often accompanied by significant extracutaneous manifestations. Management remains challenging and requires a multifaceted approach, including topical therapies, systemic retinoids and lifestyle modifications. Emerging treatments that target the underlying molecular mechanisms offer promise for improved outcomes. This review aims to provide an updated reference and practical guidance for clinicians involved in the care and study of DD.
Fecal Immunochemical Test and Multitarget Stool DNA Testing for Colorectal Cancer Screening in Real-World Practice: A Literature Review
Tiwari, Angad , Ray, Ishita , Paladiya, Ruchir, Kumar, Harendra , Sidhu, Sukhmani, Haldule, Saloni , Bharadwaj, Hareesha Rishab , Alsakarneh, Saqr, Gangwani, Manesh Kumar , Ali, Hassam, Dahiya, Dushyant Singh , Sharma, Ashish , Tiwari, Angad , Ray, Ishita , Paladiya, Ruchir , Kumar, Harendra , Sidhu, Sukhmani , Bharadwaj, Hareesha Rishab , Dahiya, Dushyant Singh , Sharma, Ashish , Alsakarneh, Saqr , Ali, Hassam

Mayo Clinic

Journal of Clinical Medicine | May 29, 2026 | Volume: 15 | Issue: 11 | Pages: 4219

10.3390/jcm15114219 | PMID 42279081 Get It

Colorectal cancer (CRC) is responsible for a high cancer burden and a high number of deaths all over the world, although effective screening can make it preventable to a significant extent. Stool-based tests, such as the fecal immunochemical test (FIT) and multitarget stool DNA (mt-sDNA) testing, are gaining considerable popularity as non-invasive procedures that can be a replacement for colonoscopies for people at an average risk for colon cancer. Despite evidence from several randomized controlled trials supporting the use of these tests for colorectal cancer screening, their external validity in a real-world setting is influenced by many factors such as adherence, timely follow-up post testing, the healthcare cost burden, accessibility and the capacity of the health system. In this article, we have performed an extensive narrative literature review of research published between 2020 and 2025 comparing FIT and the mt-sDNA test with reference to diagnostic accuracy, cost-effectiveness, adherence and outcomes of implementation. We discuss the issues of sensitivity and specificity, look at post-test requirements for colonoscopy and check if there is any discrimination in healthcare. These findings suggest that FIT and mt-sDNA tests should not be considered competing technologies but rather complementary screening methods, with their overall effectiveness contingent upon appropriate patient selection and widespread system-level implementation. It is crucial to combine strategic test selection with a robust follow-up infrastructure to ensure that the entire population benefits from the CRC prevention program.
Dexrazoxane for anthracycline cardiotoxicity prevention in pediatric and AYA cancers: Systematic review and meta-analysis.
Kumar, Harendra, Deshmukh, Sameer , Hamadah, Y , Challa, Pavan, Tiwari, Angad , Sharma, Ashish

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e24201 Get It

e24201 Background: Anthracyclines remain curative in many pediatric and adolescent/young adult (AYA) cancers but confer dose-dependent cardiotoxicity. Dexrazoxane reduces cardiac injury; however, concerns persist regarding potential impact on oncologic outcomes. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis of studies comparing anthracycline therapy with versus without dexrazoxane in pediatric/AYA populations. Databases included MEDLINE, Embase, and CENTRAL. Outcomes included cardiac function (LVEF decline, clinical heart failure), event-free survival (EFS), overall survival (OS), relapse, and second malignant neoplasms (SMN). Random-effects meta-analysis pooled hazard ratios (HRs) for time-to-event outcomes and risk ratios (RRs) for binary endpoints. Results: Twelve studies with 1,384 patients were included. Dexrazoxane significantly reduced risk of clinical heart failure (RR 0.34, 95% CI 0.21–0.55) and preserved LVEF compared with controls. No significant differences were observed in EFS (HR 0.97, 95% CI 0.84–1.12), OS (HR 0.95, 95% CI 0.81–1.11), relapse (RR 1.02, 95% CI 0.87–1.19), or SMN incidence (RR 1.05, 95% CI 0.78–1.41). Benefits were consistent across cancer types, cumulative anthracycline doses, and follow-up durations. Conclusions: Dexrazoxane provides substantial cardio protection in pediatric and AYA patients receiving anthracyclines without compromising oncologic outcomes or increasing risk of SMNs. Clinical Takeaway: Routine incorporation of dexrazoxane in high-risk anthracycline regimens can prevent cardiotoxicity while maintaining curative potential.